Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.

GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.

Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

A user's successful hair transplant, with some people questioning the donor area regrowth, and others speculating that hair fibre may have been used to help fill in areas.

A person with Alopecia Areata on their beard is using CB-03-01 and oral minoxidil for treatment. Some users question the effectiveness of CB-03-01 for beard hair, suggesting that minoxidil alone may be responsible for any observed hair growth.

The conversation discusses personal experiences with hair loss and highlights the potential impact of anemia and nutrient deficiencies on hair health. Treatments mentioned include changing shampoo/conditioner, taking MSM, collagen, hyaluronic acid, astaxanthin, B12, folate, and bovine blood capsules.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

A 36-year-old man with androgenetic alopecia suspects copper and zinc deficiencies may be accelerating hair loss and is supplementing copper to address this. He is also monitoring blood sugar levels due to previous prediabetes concerns and plans to test for insulin resistance.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.

Micronutrient testing and deficiencies related to hair loss, particularly androgenetic alopecia (AGA). Discussion includes the impact of iron, selenium, zinc, copper, folate, B12, vitamin E, vitamin D, amino acids, and fatty acids, alongside treatments like dutasteride or finasteride.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The conversation discusses a user's six-month progress in treating hereditary hair loss using a regimen that includes minoxidil, finasteride, dutasteride, and other medications. Opinions vary on the effectiveness and logic of the treatment, with some users suggesting additional methods like microneedling.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.

A user plans to create a copper peptide hair serum with GHK-Cu and AHK-Cu, considering adding 5% minoxidil but avoiding finasteride and dutasteride. They seek suggestions for improving the product without complicating it.

The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.